Compile Data Set for Download or QSAR
maximum 50k data
Found 55 Enz. Inhib. hit(s) with all data for entry = 986
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US10889546, US2007/0299086 Table 2.4 | US11426393,...)
Affinity DataIC50:  83nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107698(US11426393, Compound Table XV.4 | US8598210, Table...)
Affinity DataIC50:  180nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107714(US8598210, Table XV, 20 | US8722895, 20: {[5-(3-Cy...)
Affinity DataIC50:  190nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US10889546, US2007/0299086 Table 2.4 | US11426393,...)
Affinity DataIC50:  240nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107717(US11426393, Compound Table XV.23 | US8598210, Tabl...)
Affinity DataIC50:  300nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107708(US11426393, Compound Table XV.14 | US8598210, Tabl...)
Affinity DataIC50:  300nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  390nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107706(US11426393, Compound Table XV.12 | US8598210, Tabl...)
Affinity DataIC50:  390nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM301825(US11426393, Compound Table XV.24 | US9598370, Exam...)
Affinity DataIC50:  400nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  410nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107707(US11426393, Compound Table XV.13 | US8598210, Tabl...)
Affinity DataIC50:  440nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM301799(US11426393, Compound Table XV.8 | US9598370, Examp...)
Affinity DataIC50:  560nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107698(US11426393, Compound Table XV.4 | US8598210, Table...)
Affinity DataIC50:  650nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107706(US11426393, Compound Table XV.12 | US8598210, Tabl...)
Affinity DataIC50:  1.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  1.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataIC50:  1.20E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataIC50:  1.30E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107709(US11426393, Compound Table XV.15 | US8598210, Tabl...)
Affinity DataIC50:  1.60E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107710(US11426393, Compound Table XV.16 | US8598210, Tabl...)
Affinity DataIC50:  2.50E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107716(US11426393, Compound Table XV.22 | US8598210, Tabl...)
Affinity DataIC50:  2.50E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM301820(US11426393, Compound Table XV.19 | US9598370, Exam...)
Affinity DataIC50:  2.60E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US11426393, Compound Table XV.1 | US8598210, Table...)
Affinity DataIC50:  2.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107696(US11426393, Compound Table XV.2 | US8598210, Table...)
Affinity DataIC50:  3.70E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US11426393, Compound Table XV.6 | US8598210, Table...)
Affinity DataIC50:  4.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM301819(US11426393, Compound Table XV.18 | US9598370, Exam...)
Affinity DataIC50:  5.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM301787(US11426393, Compound Table XV.3 | US9598370, Examp...)
Affinity DataIC50:  5.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataIC50:  6.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107719(US11426393, Compound Table XV.25 | US8598210, Tabl...)
Affinity DataIC50:  9.20E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107715(US11426393, Compound Table XV.21 | US8598210, Tabl...)
Affinity DataIC50:  1.12E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107699(US11426393, Compound Table XV.5 | US8598210, Table...)
Affinity DataIC50:  2.00E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US11426393, Compound Table XV.1 | US8598210, Table...)
Affinity DataIC50:  2.14E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataIC50:  3.75E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US11426393, Compound Table XV.6 | US8598210, Table...)
Affinity DataIC50:  5.23E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM301799(US11426393, Compound Table XV.8 | US9598370, Examp...)
Affinity DataIC50:  9.90E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107709(US11426393, Compound Table XV.15 | US8598210, Tabl...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107710(US11426393, Compound Table XV.16 | US8598210, Tabl...)
Affinity DataEC50:  3.30E+3nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataEC50:  7.70E+3nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US11426393, Compound Table XV.17 | US8598210, Tabl...)
Affinity DataEC50:  1.40E+3nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US11426393, Compound Table XV.6 | US8598210, Table...)
Affinity DataEC50:  8.20E+3nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM301819(US11426393, Compound Table XV.18 | US9598370, Exam...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM301820(US11426393, Compound Table XV.19 | US9598370, Exam...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107699(US11426393, Compound Table XV.5 | US8598210, Table...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107714(US8598210, Table XV, 20 | US8722895, 20: {[5-(3-Cy...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107698(US11426393, Compound Table XV.4 | US8598210, Table...)
Affinity DataEC50:  4.21E+4nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107715(US11426393, Compound Table XV.21 | US8598210, Tabl...)
Affinity DataEC50:  5.01E+4nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM301787(US11426393, Compound Table XV.3 | US9598370, Examp...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107716(US11426393, Compound Table XV.22 | US8598210, Tabl...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107696(US11426393, Compound Table XV.2 | US8598210, Table...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107717(US11426393, Compound Table XV.23 | US8598210, Tabl...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US11426393, Compound Table XV.1 | US8598210, Table...)
Affinity DataEC50:  9.90E+3nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 55 total ) | Next | Last >>
Jump to: